We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
America Great Health (PK) | USOTC:AAGH | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.0005 | 0.0004 | 0.0006 | 0.0006 | 0.0005 | 0.0006 | 56,606,086 | 19:57:57 |
Wyoming
(State or other jurisdiction of incorporation or organization)
|
98-0178621
(I.R.S. Employer Identification No.)
|
1609 W Valley Blvd Unit 338A, Alhambra, CA
(Address of principal executive offices)
|
91803
(Zip Code)
|
Large accelerated filer
r
|
|
Accelerated filer
r
|
|
|
|
Non-accelerated filer
r
|
|
Smaller Reporting Company
☒
|
|
|
|
Emerging growth company
r
|
|
|
|
|
|
|
Page
|
PART I
|
|
|
||
Item 1.
|
|
|
4
|
|
Item 1A.
|
|
|
5
|
|
Item 1B.
|
|
|
5
|
|
Item 2.
|
|
|
5
|
|
Item 3.
|
|
|
5
|
|
Item 4.
|
|
|
5
|
|
PART II
|
|
|||
Item 5.
|
|
|
6
|
|
Item 6.
|
|
|
7
|
|
Item 7.
|
|
|
8
|
|
Item 7A.
|
|
|
10
|
|
Item 8.
|
|
|
10
|
|
Item 9.
|
|
|
10
|
|
Item 9A.
|
|
|
10
|
|
Item 9B.
|
|
|
10
|
|
PART III
|
|
|||
Item 10.
|
|
|
11
|
|
Item 11.
|
|
|
12
|
|
Item 12.
|
|
|
13
|
|
Item 13.
|
|
|
13
|
|
Item 14.
|
|
|
14
|
|
PART IV
|
|
|||
Item 15.
|
|
|
15
|
|
|
17
|
1.
|
Health & Beauty Group Inc. It is a California company in the business of R &D and sale of vitamins and nutritional supplements. It owns more than 20 formulas and engages contract manufacturers to make these products. The company has built up solid sales records both in the US as well as in China.
|
2.
|
Pro Health Inc., a Tennessee company organized in 2016. It entered into a Sales Agreement with Provision Healthcare , LLC, a Tennessee limited liability company, in the selling of ProNova Equipment, which is a Proton Treatment device used in the treatment of cancer. Other than the sale of equipment, Pro Health will also be providing Total Solution Services related with the use of the Equipment.
|
3.
|
Sales Agreement between Mike Wang and Dr. William Fang for the marketing and sales of Dr. Fang’s early detection system of Cardio Vascular diseases. The device provides unique 3D imaging for the Cardio Vascular conditions for patients and has already won approval of US FDA. It has very positive significance in helping preventing heart attacks, which are the number one killer in the US as well as in the world.
|
Fiscal Year Ended
|
|
Bid Prices
|
||||||||
June 30,
|
Period
|
High
|
Low
|
|||||||
|
|
|||||||||
2017
|
First Quarter
|
$
|
0.0070
|
$
|
0.0038
|
|||||
Second Quarter
|
$
|
0.0060
|
$
|
0.0110
|
||||||
|
Third Quarter
|
$
|
0.0061
|
$
|
0.0059
|
|||||
|
Fourth Quarter
|
$
|
0.0060
|
$
|
0.0058
|
|||||
|
|
|||||||||
2016
|
First Quarter
|
$
|
0.0090
|
$
|
0.0050
|
|||||
Second Quarter
|
$
|
0.0065
|
$
|
0.0040
|
||||||
Third Quarter
|
$
|
0.0061
|
$
|
0.0040
|
||||||
Fourth Quarter
|
$
|
0.0055
|
$
|
0.0038
|
EQUITY COMPENSATION PLAN INFORMATION
|
||||||||||||
Plan category
|
Number of securities to
be issued upon exercise
of outstanding options,
warrants and rights
(a)
|
Weighted-average
exercise price of
outstanding options,
warrants and rights
(b)
|
Number of securities
remaining available for
future issuance under
equity compensation
plans (excluding
securities reflected in
column (a))
(c)
|
|||||||||
Equity compensation plans approved
by security holders
|
0
|
$
|
0.00
|
0
|
||||||||
Equity compensation plans
not approved by security holders
|
0
|
$
|
0.00
|
0
|
||||||||
Total
|
0
|
$
|
0.00
|
0
|
Name and
Principal
Position
|
Year
|
Salary
($)
|
Bonus
($)
|
Stock
Awards
($)
|
Option
Awards
($)
|
Non-Equity
Incentive
Plan
Compensation
($)
|
Nonqualified
Deferred
Compensation
($)
|
All Other
Compensation
($)
|
Total
($)
|
|||||||||||||||||||||||||
Mike Wang
Chief Executive/Chief Financial Officer *
|
2017
|
-
|
-
|
-
|
- |
-
|
-
|
-
|
-
|
|||||||||||||||||||||||||
Herric Chan *
|
2017
|
5,000
|
- | - | - | - | - | - | - | |||||||||||||||||||||||||
Jay Hooper
Chief Executive/Chief Financial Officer * |
2016
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
CERTAIN BENEFICIAL OWNERS
|
||||||||||
Name
|
Office
|
Amount and nature of beneficial owner (1)
|
Percent
of class
|
|||||||
|
|
|||||||||
Mike Wang (2)
|
CEO, CFO, Director
|
16,155,746,000
|
80.55
|
%
|
||||||
|
|
|||||||||
All officer and directors as a group (1 person)
|
N/A
|
16,155,746,000
|
80.60
|
%
|
(1)
|
Except as otherwise noted, shares are owned beneficially and of record, and such record shareholder has sole voting, investment and dispositive power.
|
(2)
|
A change of control took place on January 19, 2017 from Jay Hooper. Control was obtained by the sale of 16,155,746,000 shares of the Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang
|
Type of Services Rendered
|
2017
|
2016
|
||||||
|
||||||||
Audit Fees
|
$
|
33,500
|
$
|
33,500
|
||||
Audit-Related Fees
|
$
|
-
|
$
|
-
|
||||
Tax Fees
|
$
|
-
|
$
|
-
|
||||
All Other Fees
|
$
|
-
|
$
|
-
|
F-1
|
|
F-2
|
|
F-3
|
|
F-4
|
|
F-5
|
|
F-6
|
|
America Great Health and Subsidiaries (fka “ Crown Marketing”)
|
||||||||||||||||||||||||||||||||
Consolidated Statement of Shareholders’ Deficit
|
||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
|
Preferred Stock
|
Common Stock
|
Additional
|
Accumulated
|
Non-Controlling
|
|||||||||||||||||||||||||||
|
Shares
|
Amount
|
Shares
|
Amount
|
Paid-in Capital
|
Deficit
|
Interest
|
Total
|
||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
Balance, June 30, 2015
|
-
|
$
|
-
|
19,981,021,800
|
$
|
-
|
$
|
-
|
$
|
(997,812
|
)
|
$
|
5,442
|
$
|
(992,370
|
)
|
||||||||||||||||
Issuance of redeemable, convertible Series A preferred stock
|
500,000
|
500,000
|
-
|
-
|
-
|
-
|
500,000
|
|||||||||||||||||||||||||
Fair value of shares issued for services
|
-
|
-
|
75,000,000
|
-
|
525,000
|
-
|
525,000
|
|||||||||||||||||||||||||
Sale of Crown Mobile shares
|
-
|
-
|
-
|
-
|
25,000
|
-
|
25,000
|
|||||||||||||||||||||||||
Reclassification of non-controlling interest
|
-
|
-
|
-
|
-
|
-
|
(4,500
|
)
|
4,500
|
-
|
|||||||||||||||||||||||
Net loss
|
(1,140,953
|
)
|
(9,942
|
) |
(1,150,895
|
)
|
||||||||||||||||||||||||||
Balance, June 30, 2016
|
500,000
|
$
|
500,000
|
20,056,021,800
|
$
|
-
|
$
|
550,000
|
$
|
(2,143,265
|
)
|
-
|
$
|
(1,093,265
|
)
|
|||||||||||||||||
|
||||||||||||||||||||||||||||||||
Gain on termination of deferred lease obligation - related party
|
-
|
-
|
-
|
-
|
636,154
|
-
|
636,154
|
|||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
Issuance of common stock upon conversion of preferred stock
|
(500,000
|
)
|
(500,000
|
)
|
80,000,000
|
-
|
500,000
|
-
|
-
|
|||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
Fair value of common stock issued to acquire trademarks
|
-
|
-
|
100,000,000
|
-
|
670,000
|
-
|
670,000
|
|||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
Gain on divestiture of subsidiaries
|
-
|
-
|
-
|
-
|
706,076
|
706,076
|
||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
Net loss
|
-
|
-
|
-
|
-
|
-
|
(967,032
|
)
|
(967,032
|
)
|
|||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||
Balance, June 30, 2017
|
-
|
$
|
-
|
20,236,021,800
|
$
|
-
|
$
|
3,062,230
|
$
|
(3,110,297
|
)
|
$
|
(48,067
|
)
|
|
Year Ended
|
|||||||
|
June 30,
|
|||||||
|
2017
|
2016
|
||||||
|
||||||||
|
||||||||
Sales
|
$
|
-
|
$
|
3,174,270
|
||||
|
||||||||
Cost of goods sold
|
-
|
2,958,763
|
||||||
|
||||||||
Gross profit
|
-
|
215,507
|
||||||
|
||||||||
Selling, general and administrative expenses:
|
||||||||
Rent expense (related party in 2016)
|
27,786
|
590,769
|
||||||
Research and development expenses
|
-
|
122,680
|
||||||
Selling, general and administrative expenses
|
859,683
|
643,278
|
||||||
Total selling, general and administrative expenses
|
887,469
|
1,356,727
|
||||||
|
||||||||
Loss from operations
|
(887,469
|
)
|
(1,141,220
|
)
|
||||
|
||||||||
Other expenses
|
||||||||
Rental income
|
-
|
45,300
|
||||||
Interest expense, related party
|
(31,197
|
)
|
(54,975
|
)
|
||||
|
(31,197
|
)
|
(9,675
|
)
|
||||
|
||||||||
NET LOSS
|
$
|
(918,666
|
)
|
$
|
(1,150,895
|
)
|
||
|
||||||||
Net loss attributable to non-controlling interest
|
-
|
(9,942
|
)
|
|||||
|
||||||||
NET LOSS ATTRIBUTABLE TO AMERICA GREAT HEALTH
|
$
|
(918,666
|
)
|
$
|
(1,140,953
|
)
|
||
|
||||||||
BASIC AND DILUTED LOSS PER SHARE
FROM DISCONTINUED OPERATIONS
|
$
|
(0.00
|
)
|
$
|
(0.00
|
)
|
||
|
||||||||
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING
BASIC AND DILUTED
|
20,182,268,375
|
20,049,446,458
|
|
June 30, 2017
|
June 30, 2016
|
||||||
|
||||||||
Note payable, interest at 12% per annum, secured by essentially all assets of the Company, due July 31, 2017. The lender is Temple CB LLC (“Temple”), a limited liability company controlled by Jay Hooper, the Company’s President and majority shareholder
|
$
|
-
|
$
|
531,975
|
||||
Note payable to Jay Hooper, due on demand, interest at 4% per annum
|
-
|
10,000
|
||||||
|
-
|
541,975
|
||||||
Less: current portion
|
-
|
(10,000
|
)
|
|||||
Notes payable, non-current portion
|
$
|
-
|
$
|
531,975
|
Year Ended June 30,
|
||||||||
2017
|
2016
|
|||||||
Income tax benefit at federal statutory rate
|
34
|
%
|
34
|
%
|
||||
State tax, net of fed effect
|
6
|
%
|
6
|
%
|
||||
Change in valuation allowance
|
-40
|
%
|
-40
|
%
|
||||
-
|
%
|
-
|
%
|
June 30, 2017
|
June 30, 2016
|
|||||||
Stock based compensation
|
$
|
-
|
$
|
210,000
|
||||
Net operating loss carryforwards
|
48,366
|
647,306
|
||||||
Less: valuation allowance
|
(48,366
|
)
|
(857,306
|
)
|
||||
Net deferred tax assets
|
$
|
-
|
$
|
-
|
AMERICA GREAT HEALTH
|
|
|
Date: February 23, 2018
|
|
/s/ Mike Wang
|
|
|
|
Mike Wang, Chief Executive Officer,
Chief Financial Officer, Secretary and Director
|
|
Date: February 23, 2018
|
|
/s/ Mike Wang
|
|
|
|
Mike Wang, Chief Executive Officer,
Chief Financial Officer, Secretary and Director
|
|
1 Year America Great Health (PK) Chart |
1 Month America Great Health (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions